• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Standard BioTools Inc. (Amendment)

    1/12/24 2:04:47 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    SC 13D/A 1 formsc13da-01122024_070144.htm FORM schedule-13d


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*


     
    STANDARD BIOTOOLS INC.
    (Name of Issuer)
    Common
    (Title of Class of Securities)
    34385P108
    (CUSIP Number)
    William Braverman ESQ
    Neuberger Berman Group LLC
    1290 Avenue of the Americas
    New York , New Jersey 10104
    212-476-9035
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    January 5, 2024
    (Date of Event which Requires Filing of this Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ x ]
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Group LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        Common

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        3,500,017

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        4,382,584

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        4,382,584

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares    [ x ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        1.51

    (14)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Investment Advisers Holdings LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        3,432,661

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        4,315,228

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        4,315,228

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        1.49

    (14)

     

    Type of Reporting Person (See Instructions)

     

        OO


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Investment Advisers LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        3,432,661

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        4,315,228

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        4,315,228

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        1.49

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IA


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Canada Holdings LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        67.356

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        67,356

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        67,356

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.02

    (14)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        NB Acquisitionco ULC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        British Columbia, Canada

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        67,356

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        67,356

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        67,356

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.02

    (14)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Canada ULC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        OO

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        British Columbia, Canada

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        0

       (8)   

    Shared Voting Power

     

        67,356

       (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        67,356

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        67,356

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.02

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IA


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Benjamin Nahum

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        PF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        315,000

       (8)   

    Shared Voting Power

     

        0

       (9)   

    Sole Dispositive Power

     

        315,000

       (10)   

    Shared Dispositive Power

     

        0

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        315,000

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        .11

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IN


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Amit Solomon

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        PF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        9,260

       (8)   

    Shared Voting Power

     

        0

       (9)   

    Sole Dispositive Power

     

        9,260

       (10)   

    Shared Dispositive Power

     

        0

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        9,260

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.00

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IN


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Rand Gesing

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        PF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        50,000

       (8)   

    Shared Voting Power

     

        0

       (9)   

    Sole Dispositive Power

     

        50,000

       (10)   

    Shared Dispositive Power

     

        0

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        50,000

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.02

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IN


    CUSIP No. 34385P108
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Pong Chan

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (b)  Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

        PF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [   ]

      (6)  

    Citizenship or Place of Organization

     

        United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (7)    

    Sole Voting Power

     

        2,000

       (8)   

    Shared Voting Power

     

        0

       (9)   

    Sole Dispositive Power

     

        2,000

       (10)   

    Shared Dispositive Power

     

        0

    (11)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        2,000

    (12)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares  [   ]

    (13)

     

    Percent of Class Represented by Amount in Row (9)

     

        0.00

    (14)

     

    Type of Reporting Person (See Instructions)

     

        IN


    Item 1. Security and Issuer
    Item 1 of the Schedule 13D is hereby amended and supplemented as follows:

    This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the information set forth in the Schedule 13D filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the "SEC") on November 18, 2021 ("Amendment No.1" and, together with the Initial Schedule 13D, the "Schedule 13D"), relating to the class of equity securities to which this statement on Schedule 13D relates is the common stock (the "Securities") of Standard Biotools Inc., a California corporation (the "Issuer"), having its principal place of business at 2 Tower Place, Suite 2000 South San Francisco, CA, 94080. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D.
    Item 2. Identity and Background
    (c)
    Item 2(c) of the Schedule 13D is hereby amended to restate the information required by instruction C to Schedule 13D as follows:

    The information required by instruction C to Schedule 13D with respect to the directors and executive officers of the Reporting Persons is set forth below.

    Neuberger Berman Group LLC

    Directors
    Joseph Amato
    Sharon Bowen
    Robert D'Alelio
    Michele Docharty
    Steven Kandarian
    George Walker
    Richard Worley

    Executive Officers
    George Walker, Chief Executive Officer
    Joseph Amato, President
    Andrew Komaroff, Executive Vice President and Chief Operating Officer
    Heather Zuckerman, Executive Vice President, Chief of Staff and Secretary
    William Arnold, Executive Vice President and Chief Financial Officer
    Michael Chinni, Treasurer
    Leo Anthony Viola, Controller

    Neuberger Berman Investment Advisers LLC

    Directors
    Joseph Amato
    Kenneth deRegt
    Douglas Kramer
    Bradley Tank
    Stephen Wright

    Executive Officers
    Joseph Amato, President - Equities and Chief Investment Officer – Equities
    Bradley Tank, President - Fixed Income and Chief Investment Officer – Fixed Income
    Kenneth deRegt, Chief Operating Officer - Fixed Income and Managing Director
    Patrick Deaton - Chief Operating Officer - Alternatives and Managing Director
    Paul Lanks - Chief Operating Officer - Private Wealth
    Douglas Kramer, Head of Institutional Equity and Multi-Asset and Managing Director
    Irina Babushkina, Chief Administrative Officer - Global Research and Senior Vice President
    Beryl Lou, Head of Investment Engineering and Vice President
    Brian Kerrane, Head of Mutual Fund Administration and Managing Director
    Brad Cetron, Chief Compliance Officer, Head of Compliance and Managing Director
    Michael Chinni, Treasurer and Senior Vice President
    Leo Anthony Viola, Controller and Managing Director
    Savonne Ferguson, Chief Compliance Officer - Mutual Funds and Senior Vice President



    Neuberger Berman Canada ULC

    Directors
    Joseph Amato
    Heather Zuckerman
    Ray Carroll
    Patrick Deaton

    Executive Officers
    Kashif Khan, Chief Executive Officer
    Ray Carroll, Chief Investment Officer - Breton Hill
    William Arnold, Chief Financial Officer
    Leo Anthony Viola, Controller
    Milca Beltre, Head of Tax
    Barry Giarraputo, Chief Financial Officer - Alternatives
    Brian Kerrane, Head of Fund Administration
    Robert Arancio, Head of Trading
    Patrick Lomelo, Head of Operations
    Viviana Beltrametti Walker, Chief Compliance Officer
    Linda Sharaby, Secretary
    Monica Sherer, Assistant Secretary
    Elvira Decaro, Assistant Secretary
    Frank Maeba, Managing Director
    Simon Griffiths, Managing Director
    Gideon Schapiro, Managing Director
    Ram Ramaswamy, Managing Director
    Evgeny Dunaevsky, Senior Vice President


    Item 5. Interest in Securities of the Issuer.
    (a)
    Item 5 (a) - (c) and (e) of the Schedule 13D is hereby amended and supplemented as follows:

    See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of and percentages of the shares of Common Stock beneficially owned by each Reporting Person. The percentages set forth in this Schedule 13D are based upon the Reporting Person's calculation of 289,464,031 shares of Common Stock outstanding, based upon (i) 80,030,193 shares of Common Stock outstanding as of November 29, 2023, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on December 22, 2023 ("the Prospectus"), plus (ii) 209,433,838 shares of Common Stock used as merger consideration in connection with the Issuer's transaction with SomaLogic, Inc., a Delaware corporation ("Somalogic") (representing a 1.11 fixed exchange ratio over 188,679,133 shares of SomaLogic common stock outstanding as of November 29, 2023, as reported in the Prospectus). As a result of the consummation of the transaction between the Issuer and SomaLogic (as reported in the Form 8-K filed by the Issuer on January 5, 2024), the Reporting Persons' beneficial ownership of Common Stock has been reduced below 5% of the outstanding shares of Common Stock.
    (b)
    See Rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
    (c)
    Information concerning transaction in the shares of Common Stock reported herein effected during the past sixty (60) days is set forth in Schedule 1, which is attached hereto and is incorporated herein by reference. All of the transactions in the shares of Common Stock listed therein were effected in the open market through various brokerage entities.
    (d)
    The Reporting Persons effected the following transactions in the Securities during the past sixty days. Such transactions were effected in the open market.

    See Schedule 1.
    (e)
    January 5, 2024
    Item 7. Material to Be Filed as Exhibits
    EX-1.1
      
    The Reporting Persons effected the following transactions in the Securities during the past sixty days. Such transactions were effected in the open market.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   January 12, 2024
    Neuberger Berman Group LLC
    By: /s/ Joseph Amato

    Name: Joseph Amato
    Title: President
    Date:   January 12, 2024
    Neuberger Berman Investment Advisers LLC
    By: /s/ Joseph Amato

    Name: Joseph Amato
    Title: President - Equities
    Date:   January 12, 2024
    Neuberger Berman Investment Advisers Holdings LLC
    By: /s/ Andrew Komaroff

    Name: Andrew Komaroff
    Title: President
    Date:   January 12, 2024
    Neuberger Berman Canada Holdings LLC
    By: /s/ Ray Carroll

    Name: Ray Carroll
    Title: Chief Executive Officer
    Date:   January 12, 2024
    NB Acquisitionco ULC
    By: /s/ Ray Carroll

    Name: Ray Carroll
    Title: Chief Executive Officer
    Date:   January 12, 2024
    Neuberger Berman Canada ULC
    By: /s/ Ray Carroll

    Name: Ray Carroll
    Title: Chief Executive Officer
    Date:   January 12, 2024
    By: /s/ Benjamin Nahum

    Name: Benjamin Nahum
    Date:   January 12, 2024
    By: /s/ Amit Solomon

    Name: Amit Solomon
    Date:   January 12, 2024
    By: /s/ Rand Gesing

    Name: Rand Gesing
    Date:   January 12, 2024
    By: /s/ Pong Chan

    Name: Pong Chan


    Exhibit Index
     
    Exhibit No.

      
    Description

    EX-1.1
      
    The Reporting Persons effected the following transactions in the Securities during the past sixty days. Such transactions were effected in the open market.
    Get the next $LAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    8/13/2025$1.55Buy → Hold
    TD Cowen
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/26/25 4:58:37 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $1,374,575 worth of shares (1,075,000 units at $1.28) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/20/25 7:45:54 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Standard BioTools downgraded by TD Cowen with a new price target

    TD Cowen downgraded Standard BioTools from Buy to Hold and set a new price target of $1.55

    8/13/25 8:03:50 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

    2/27/25 6:22:46 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    TD Cowen initiated coverage on Standard BioTools with a new price target

    TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

    4/16/24 8:09:43 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/26/25 4:58:37 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Egholm Michael covered exercise/tax liability with 63,529 shares, decreasing direct ownership by 1% to 5,617,837 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/24/25 5:05:15 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    SEC Filings

    View All

    Amendment: Standard BioTools Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    2/5/26 4:38:13 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    1/30/26 9:18:32 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    1/8/26 7:10:25 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Standard BioTools Completes Sale of SomaLogic to Illumina

    Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina") for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggreg

    1/30/26 9:09:00 AM ET
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million. For the full year 2025, the Company expects combined company revenue of approximately $185 million and revenue from continued operations of approximately $85 million. "Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and con

    1/8/26 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

    Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and Standard BioTools Inc. (NASDAQ:LAB) today announced a strategic collaboration to develop next-generation Imaging Mass Cytometry™ (IMC™) workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody. The partnership combines HCR Gold for RNA and protein imaging with the Standard BioTools™ Hyperion™ Imaging System, extending the reach of IMC technology by introducing amplified detection for both RNA and protein for the first time.

    11/19/25 11:30:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    View All

    Standard BioTools Appoints Alex Kim as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

    11/7/24 8:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

    5/15/23 7:30:14 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/12/24 6:01:47 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/4/24 1:59:57 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Financials

    Live finance-specific insights

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Reports First Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

    5/6/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials